Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 19/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835568 | 0.81 | NR3C1 (0.52) | NR3C1PGR | |
| SCHEMBL443447 | 0.80 | PLK1 (0.41) | NR3C1PGR | |
| SCHEMBL413083 | 0.79 | NR3C1 (0.71) | NR3C1PGR | |
| SCHEMBL445472 | 0.79 | NR3C1 (0.71) | NR3C1PGR | |
| SCHEMBL835586 | 0.78 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL412277 | 0.78 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL12101194 | 0.78 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL5140930 | 0.77 | NR3C1 (0.59) | NR3C1PGRCYP17A1CYP1A2 | |
| SCHEMBL4113075 | 0.77 | NR3C1 (0.59) | NR3C1PGRCYP17A1CYP1A2 | |
| SCHEMBL4123716 | 0.75 | CYP17A1 (0.55) | NR3C1CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097384-B1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | BERGER MARKUS (DE) | 2012-03-15 | — | — | US | disclosed |
| US-8030340-B2 | Moderators of glucocorticoids receptor; antiinflamamtory agents; chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 263/4885CYP17A1 30/4885 |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 281/4885CYP17A1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.